FLOWSION-A/S
9.7.2021 13:24:06 CEST | Business Wire | Press release
Flowsion, the Denmark-based developer of automated continuous blood glucose control systems for intensive care medicine, today announced the CE (Conformité Européenne) Mark for its Glycostat™ automated glucose control system for intensive care medicine; GlycostatTM is the only blood glucose control system to be launched in the European Union (EU) with an algorithm which enables automated blood glucose control for patients in intensive care.
“With the CE mark we have reached an important milestone in our efforts to help patients and hospitals solving the important problem of glycemic control in the intensive care unit (ICU). For Flowsion this opens a globally relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we know already that Glycostat fulfils the demands of the intensive care units.”
“This kind of technology is really crucial for intensive care medicine, where patients’ lifes are threatened every day. Glucose control has proven to be very difficult to perform for the intensive care units in hospitals worldwide, and now getting a system that automatically helps performing blood glucose control will increase survival rate and lower treatment costs at the same time” said Hans Jorgen Pedersen. “We’ve carefully studied several technologies and designed a solution that is really elegant and simple to use, but that also delivers an enormous value for patients, doctors, nurses and hospitals.”
Flowsion has received support from The EU SME program which is designed to assist internationally oriented SMEs in implementing high-risk and high-potential innovation ideas. It aims at supporting projects with a European dimension that lead to major changes in how business is done.
About Flowsion
Flowsion is a European medical device company focusing exclusively on the needs of intensive care unit patients. Flowsion will launch new projects later on with other continuous measurement and control technologies for the ICU patients. More information can be found at: http://flowsion.dk
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 14:01:00 CEST | Press release
14 ADX-listed companies will present their growth strategies and equity stories to international investors The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explo
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial22.9.2026 14:00:00 CEST | Press release
– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline –- In people with AMKD and type 2 diabetes, treatment with inaxaplin led to a reduction in UACR of -17.3% at Week 13 compared to baseline –- Inaxaplin was generally safe and well tolerated in both cohorts –- Vertex has completed enrollment in the AMPLITUDE trial and remains on track for interim analysis results in early 2027, which, if positive could support potential accelerated approval in the US - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) peop
INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth22.9.2026 14:00:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) (“INNIO” or the “Company”) today announced that Fitch Ratings has upgraded the Company’s credit ratings, following a recent upgrade by Moody’s Ratings. INNIO also reaffirmed its financial policy framework, which supports investment in profitable growth while continuing to strengthen the Company’s balance sheet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922051908/en/ INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth Credit rating upgrades Moody’s upgraded INNIO’s Corporate Family Rating by one notch to Ba3 from B1 and revised the outlook to positive from stable. Fitch Ratings upgraded INNIO’s Long-Term Issuer Default Rating by two notches to BB from B+, with a stable outlook. Fitch also upgraded INNIO’s senior secured debt rating to BB+ from B+. These upgrades reflect INNIO’s strong operating performance and cash flow generation, supported by fa
Who Decides What’s Safe Online? Trust Issues Returns for Season 222.9.2026 14:00:00 CEST | Press release
WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922209613/en/ WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. Who ultimately decides what stays up and what comes down in digital spaces? Season 2 answers that question by examining how AI capabilities, shifting market place regulations, human judgement and operational constraints intersect. Moving beyond simple technical solutions, each episode goes behind the scenes of the complex pressures facing digital platforms today, from cost efficiencies to high stake compliance, and the strategies leaders use to b
Manhattan Associates Announces EditionsTM for its Industry-Leading Solutions, Making Them Accessible at Every Stage of Growth22.9.2026 14:00:00 CEST | Press release
New offering gives commercial and growing enterprises the right-sized path to start their journey with Manhattan, and scale on the same platform as their business grows Manhattan Associates (NASDAQ: MANH), the global leader in supply chain commerce with unmatched AI capabilities, today announced the commercial launch of Editions for Manhattan Active® solutions. Editions provide a new way for companies of all sizes and across industries to partner with Manhattan. They are designed to help growing organizations make a durable, long-term technology decision from the start. As complexity increases, customers can unlock additional capabilities on the same platform, rather than starting over. Built for ActiveWarehouse™, ActiveTransportation™, ActiveStore™ and ActiveOrder™, on Manhattan’s award-winning ActivePlatform™, there are three Editions available: Essentials, Enterprise and Enterprise Premier. Regardless of the Edition selected for each solution, companies gain access to the power of a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom